These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33565241)

  • 1. BRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakers.
    Jain P; Surrey LF; Straka J; Russo P; Womer R; Li MM; Storm PB; Waanders AJ; Hogarty MD; Resnick AC; Picarsic J
    Pediatr Blood Cancer; 2021 Jun; 68(6):e28933. PubMed ID: 33565241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.
    Jain P; Fierst TM; Han HJ; Smith TE; Vakil A; Storm PB; Resnick AC; Waanders AJ
    Oncogene; 2017 Nov; 36(45):6348-6358. PubMed ID: 28806393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.
    Basile KJ; Le K; Hartsough EJ; Aplin AE
    Pigment Cell Melanoma Res; 2014 May; 27(3):479-84. PubMed ID: 24422853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
    Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
    Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.
    Diamond EL; Durham BH; Haroche J; Yao Z; Ma J; Parikh SA; Wang Z; Choi J; Kim E; Cohen-Aubart F; Lee SC; Gao Y; Micol JB; Campbell P; Walsh MP; Sylvester B; Dolgalev I; Aminova O; Heguy A; Zappile P; Nakitandwe J; Ganzel C; Dalton JD; Ellison DW; Estrada-Veras J; Lacouture M; Gahl WA; Stephens PJ; Miller VA; Ross JS; Ali SM; Briggs SR; Fasan O; Block J; Héritier S; Donadieu J; Solit DB; Hyman DM; Baselga J; Janku F; Taylor BS; Park CY; Amoura Z; Dogan A; Emile JF; Rosen N; Gruber TA; Abdel-Wahab O
    Cancer Discov; 2016 Feb; 6(2):154-65. PubMed ID: 26566875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF paradox breakers PLX8394, PLX7904 are more effective against BRAFV600Ε CRC cells compared with the BRAF inhibitor PLX4720 and shown by detailed pathway analysis.
    Koumaki K; Kontogianni G; Kosmidou V; Pahitsa F; Kritsi E; Zervou M; Chatziioannou A; Souliotis VL; Papadodima O; Pintzas A
    Biochim Biophys Acta Mol Basis Dis; 2021 Apr; 1867(4):166061. PubMed ID: 33385518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
    Hutchinson KE; Lipson D; Stephens PJ; Otto G; Lehmann BD; Lyle PL; Vnencak-Jones CL; Ross JS; Pietenpol JA; Sosman JA; Puzanov I; Miller VA; Pao W
    Clin Cancer Res; 2013 Dec; 19(24):6696-702. PubMed ID: 24345920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic
    Miyauchi S; Shien K; Takeda T; Araki K; Nakata K; Miura A; Takahashi Y; Kurihara E; Ogoshi Y; Namba K; Suzawa K; Yamamoto H; Okazaki M; Soh J; Tomida S; Yamane M; Sakaguchi M; Toyooka S
    Anticancer Res; 2020 May; 40(5):2667-2673. PubMed ID: 32366411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diverse
    Stangl C; Post JB; van Roosmalen MJ; Hami N; Verlaan-Klink I; Vos HR; van Es RM; Koudijs MJ; Voest EE; Snippert HJG; Kloosterman WP
    Mol Cancer Res; 2020 Apr; 18(4):537-548. PubMed ID: 31911540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming resistance to single-agent therapy for oncogenic
    Jain P; Silva A; Han HJ; Lang SS; Zhu Y; Boucher K; Smith TE; Vakil A; Diviney P; Choudhari N; Raman P; Busch CM; Delaney T; Yang X; Olow AK; Mueller S; Haas-Kogan D; Fox E; Storm PB; Resnick AC; Waanders AJ
    Oncotarget; 2017 Oct; 8(49):84697-84713. PubMed ID: 29156677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
    Peng SB; Henry JR; Kaufman MD; Lu WP; Smith BD; Vogeti S; Rutkoski TJ; Wise S; Chun L; Zhang Y; Van Horn RD; Yin T; Zhang X; Yadav V; Chen SH; Gong X; Ma X; Webster Y; Buchanan S; Mochalkin I; Huber L; Kays L; Donoho GP; Walgren J; McCann D; Patel P; Conti I; Plowman GD; Starling JJ; Flynn DL
    Cancer Cell; 2015 Sep; 28(3):384-98. PubMed ID: 26343583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets.
    Chen MF; Yang SR; Tao JJ; Desilets A; Diamond EL; Wilhelm C; Rosen E; Gong Y; Mullaney K; Torrisi J; Young RJ; Somwar R; Yu HA; Kris MG; Riely GJ; Arcila ME; Ladanyi M; Donoghue MTA; Rosen N; Yaeger R; Drilon A; Murciano-Goroff YR; Offin M
    Clin Cancer Res; 2024 Sep; 30(17):3812-3823. PubMed ID: 38922339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation.
    Tutuka CSA; Andrews MC; Mariadason JM; Ioannidis P; Hudson C; Cebon J; Behren A
    Mol Cancer; 2017 Jun; 16(1):112. PubMed ID: 28659148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF fusions identified in melanomas have variable treatment responses and phenotypes.
    Turner JA; Bemis JGT; Bagby SM; Capasso A; Yacob BW; Chimed TS; Van Gulick R; Lee H; Tobin R; Tentler JJ; Pitts T; McCarter M; Robinson WA; Couts KL
    Oncogene; 2019 Feb; 38(8):1296-1308. PubMed ID: 30254212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association.
    Vido MJ; Le K; Hartsough EJ; Aplin AE
    Cell Rep; 2018 Nov; 25(6):1501-1510.e3. PubMed ID: 30404005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A circulating subset of BRAF
    Poch R; Le Louet S; Hélias-Rodzewicz Z; Hachem N; Plat G; Barkaoui MA; Lapillonne H; Delhommeau F; Emile JF; Donadieu J; Héritier S
    Br J Haematol; 2021 Aug; 194(4):745-749. PubMed ID: 34312844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
    Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
    Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel GAB2::BRAF fusion in cutaneous non-Langerhans-cell histiocytosis with systemic involvement.
    Wu B; Konnick EQ; Kimble EL; Hendrie PC; Shinohara MM; Moshiri AS
    J Cutan Pathol; 2022 Aug; 49(8):727-730. PubMed ID: 35332933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New somatic BRAF splicing mutation in Langerhans cell histiocytosis.
    Héritier S; Hélias-Rodzewicz Z; Chakraborty R; Sengal AG; Bellanné-Chantelot C; Thomas C; Moreau A; Fraitag S; Allen CE; Donadieu J; Emile JF
    Mol Cancer; 2017 Jul; 16(1):115. PubMed ID: 28679432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
    Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
    J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.